Loading
Cancer Cells and Metastasis / Gastrointestinal Tumor Research and Treatment / Gastric Cancer Management and Outcomes · Journal article
World Journal of Translational Medicine · September 4, 2026
Raises a question worth testing. It does not answer one.
This paper presents a conceptual framework—termed heterogeneity-oriented multidisciplinary and super-minimally invasive precision treatment—for managing locally advanced gastric cancer (cT3-T4a). The authors explicitly state the model lacks primary clinical data and that claims of lower morbidity or superior outcomes are unsupported. The framework is offered as a testable hypothesis for future prospective validation rather than an established clinical alternative.
Journal article. Locally advanced gastric cancer (cT3-T4a ± regional lymph node involvement, M0). Intervention: Heterogeneity-oriented multidisciplinary and super-minimally invasive precision resection framework: preoperative heterogeneity mapping, multidisciplinary decision-making, endoscopic/laparoscopic/combined resection, serosal-peritoneal and…. Compared with: Standard perioperative systemic therapy and gastrectomy with D2 lymphadenectomy (described as established reference, not formally compared).
Framework proposes preoperative probabilistic heterogeneity mapping, heterogeneity-focused multidisciplinary decision-making, and anatomically appropriate local treatment using endoscopic, laparoscopic, or combined approaches Endoscopic super minimally invasive surgery alone is deemed insufficient for cT3-T4a disease; cT4a serosal involvement requires laparoscopic evaluation and oncological control Authors explicitly state 'The model currently lacks primary clinical data, and claims of lower morbidity or superior long-term outcomes are not supported'
No primary clinical outcome data reported; no morbidity, mortality, recurrence, or survival statistics provided
This framework should not yet guide clinical practice. Clinicians should continue with standard perioperative systemic therapy and gastrectomy with D2 lymphadenectomy as the established curative-intent treatment while awaiting prospective validation studies.
This is a conceptual framework paper proposing a treatment approach for locally advanced gastric cancer, explicitly lacking primary clinical data and validation, presented as a hypothesis-driven concept requiring future prospective testing.
As stated by the source record.
This framework should not yet guide clinical practice. Clinicians should continue with standard perioperative systemic therapy and gastrectomy with D2 lymphadenectomy as the established curative-intent treatment while awaiting prospective validation studies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Locally advanced gastric cancer, defined here as cT3-T4a disease with or without regional lymph node involvement and without distant metastasis, is characterized by substantial spatial and clonal heterogeneity.Distinct hypoxic, proliferative, invasive, immune-evasive, and treatment-resistant subpopulations may coexist within the primary tumor, the serosal-peritoneal interface, and regional lymph nodes.Standard perioperative systemic therapy and gastrectomy with D2 lymphadenectomy remain the established curative-intent treatment for resectable locally advanced gastric cancer; however, a uniform stage-based strategy may not fully represent the biological complexity of these tumors.To this end, we refined the Heterogeneity-oriented multidisciplinary team planning and super minimally invasive precision resection concept as a hypothesis-driven treatment framework rather than a clinically validated alternative to standard surgery.The framework comprises preoperative probabilistic heterogeneity mapping, heterogeneity-focused multidisciplinary decision-making, anatomically appropriate local treatment using endoscopic, laparoscopic or combined approaches, explicit management of the serosal-peritoneal and regional lymph node compartments, and postoperative biomarker-informed and risk-informed therapy.The proposed functional zones are not fixed anatomical layers, and endoscopic super minimally invasive surgery alone is insufficient for cT3-T4a disease.In particular, cT4a serosal involvement belongs to a serosal-peritoneal interface zone that requires laparoscopic evaluation and oncological control, while regional nodal disease requires guideline-concordant lymph node management.The model currently lacks primary clinical data, and claims of lower morbidity or superior long-term outcomes are not supported.Future validation should entail radiologic and pathologic mapping studies, followed by prospective feasibility studies measuring technical success, R0 resection, serosal and nodal control, perioperative complications, functional preservation, recurrence and survival.Heterogeneity-oriented multidisciplinary team planning and super minimally invasive precision resection should therefore be viewed as a testable framework for selected patients and clinical trials, with oncological adequacy taking priority over organ preservation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.